How Did Breast Cancer Patients Fare during Different Phases of the COVID-19 Pandemic in Norway Compared to Age-Matched Controls?

Author:

Svendsen Karianne123ORCID,Leithe Sigrid1,Trewin-Nybråten Cassia B.1ORCID,Balto Aina1,Nes Lise Solberg456,Meland Anders7,Børøsund Elin48,Kiserud Cecilie E.9,Reinertsen Kristin Valborg9,Eriksen Hege R.10ORCID,Gjelsvik Ylva Maria1,Ursin Giske1211

Affiliation:

1. Cancer Registry of Norway, Norwegian Institute of Public Health, 0379 Oslo, Norway

2. Department of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, 0317 Oslo, Norway

3. The Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, 0586 Oslo, Norway

4. Department of Digital Health Research, Division of Medicine, Oslo University Hospital, 0586 Oslo, Norway

5. Department of Psychiatry and Psychology, Mayo Clinic College of Medicine and Science, Mayo Clinic, Rochester, MN 55905, USA

6. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0318 Oslo, Norway

7. Department of Social Sciences, Norwegian School of Sport Sciences, 0863 Oslo, Norway

8. Department of Nursing and Health Sciences, Faculty of Health and Social Sciences, University of South-Eastern Norway, 3054 Drammen, Norway

9. Department of Oncology, Oslo University Hospital, 0310 Oslo, Norway

10. Department of Sport, Food and Natural Sciences, Western Norway University of Applied Sciences, 5020 Bergen, Norway

11. Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA 90033, USA

Abstract

Little is known about how health-related quality of life (HRQoL) in breast cancer cases differed from that of controls during and after the COVID-19 pandemic. This study used data from an ongoing, nationwide HRQoL survey of 4279 newly diagnosed breast cancer cases and 2911 controls to investigate how breast cancer patients fared during different phases of the pandemic compared to controls. Responders during 2020–2022 were categorized into three COVID-19-related phases: the social restrictions phase, the high infection rate phase, and the post-pandemic phase. Across phases, breast cancer cases had significantly worse scores in most HRQoL domains compared to controls. Apart from slightly more insomnia in the high infection rate phase for both cases and controls, and better social functioning for young cases in the post-COVID-19 phase, the case-control differences in HRQoL remained consistent across phases. When the phases were assessed as one period, young women and those living with children <18 years of age fared the worst among breast cancer cases, while single women fared the worst among controls. In contrast, controls living with children <18 years of age exhibited better HRQoL than controls without children. In summary, women with breast cancer did not appear to fare differently than controls in terms of HRQoL across COVID-19 phases. However, breast cancer cases with young children fared worse in their HRQoL than other breast cancer cases.

Funder

Norwegian Breast Cancer Society’s “Pink Ribbon”

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference36 articles.

1. World Health Organization (2023, December 04). WHO Director-General’s opening remarks at the media briefing on COVID-19. Available online: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.

2. Impact of the COVID-19 Pandemic on Patient-Reported Outcomes of Breast Cancer Patients and Survivors;Bargon;JNCI Cancer Spectr.,2021

3. Organization for Economic Co-operation and Development (2021). OECD/European Observatory on Health Systems and Policies, Norway: Country Health Profile 2021—State of Health in the EU, Organization for Economic Co-operation and Development.

4. The impact of COVID-19 on health and health systems;Haileamlak;Ethiop. J. Health Sci.,2021

5. The Cancer Registry of Norway (2023). Cancer in Norway 2022—Cancer Incidence, Mortality, Survival and Prevalence in Norway, The Cancer registry of Norway.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3